GlassScriptPhysician profile
Nino P Soave
NPI 1053539007
$3,506.84
in general payments reported to CMS, 2019-2025
18 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.62 · 2020: $54.72 · 2021: $216 · 2022: $652 · 2023: $694 · 2024: $959 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.04 |
| Education | $227.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $713.42 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $574.55 | 2019-2025 | Rinvoq, Skyrizi |
| Boston Scientific Corporation | $534.54 | 2023-2025 | Resolution 360 Clip, Exalt Model D, Resolution 360 Ultra Clip |
| Janssen Biotech, INC. | $436.82 | 2021-2025 | Stelara, Tremfya, Simponi |
| Braintree Laboratories, INC. | $215.58 | 2021-2025 | Sutab, Suflave |
| Celgene Corporation | $197.00 | 2021-2022 | |
| Genzyme Corporation | $190.83 | 2022-2024 | |
| Madrigal Pharmaceuticals | $184.49 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $113.18 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $105.99 | 2022 | |
| Pfizer INC. | $93.35 | 2024 | |
| Novo Nordisk INC | $23.95 | 2025 | Wegovy |
| Qol Medical, LLC | $22.29 | 2024 | Sucraid |
| Janssen Scientific Affairs, LLC | $21.49 | 2023 | Stelara |
| Aimmune Therapeutics, INC. | $20.83 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $20.64 | 2023 | Idacio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2020 | |
| Shionogi INC | $17.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nino Soave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.